Hematin 

Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins^[1]. Hematin can be used for the research of acute porphyrias and cancer^{[1][2][3][4][5]}.

Hematin (0.01 mg/ml) inhibits the clotting of bovine fibrinogen (1.3 to 2.6 mg/ml) by bovine thrombin (0.12 U/ml) and inhibits the hydrolysis of a synthetic substrate by human thrombin^[2].
Hematin (0.035 mg/ml) reduces VIII:C activity from 0.88 to 0.40 U/ml^[2].
Hematin (0.05 mg/ml) inhibits the activation of VIII:C by thrombin (0.04 U/ml)^[2].
Hematin (0.09 mg/ml) inhibits the hydrolysis of a synthetic substrate by plasmin^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Hematin (i.v.; single injection) suppressed porphyrin production in SD rat (weighing 160-205 g)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

633.49

C₃₄H₃₃FeN₄O₅

15489-90-4

Solid

Purple to black

CC1=C(CCC(O)=O)C([N-]C1=CC(C(C)=C2C=C)=NC2=CC3=C4C)=CC(C(CCC(O)=O)=C5C)=NC5=CC([N-]3)=C4C=C.[Fe+3].[OH-]

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Siegert SW, et al. Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review. Adv Ther. 2008 Sep;25(9):842-57.  [Content Brief]

  [2]. Green D, et al. The inactivation of hemostatic factors by hematin. J Lab Clin Med. 1983;102: 361-369.  [Content Brief]

  [3]. Amin ML, et al. Development of hematin conjugated PLGA nanoparticle for selective cancer targeting. Eur J Pharm Sci. 2016 Aug 25;91:138-43.  [Content Brief]

  [4]. Goetsch C, et al. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315: 235-238.  [Content Brief]

  [5]. Quadros HC, et al. The Role of the Iron Protoporphyrins Heme and Hematin in the Antimalarial Activity of Endoperoxide Drugs. Pharmaceuticals (Basel). 2022;15(1):60. Published 2022 Jan 4.  [Content Brief]